Abstract
The extent and complications of the interaction between capecitabine and warfarin are not fully known. A retrospective study of 77 patients who received capecitabine was performed to analyze coagulation abnormalities with or without warfarin. Twenty-one patients received warfarin with capecitabine. Twelve were on an average warfarin dosage of 19.4 mg per week (range, 7-35 mg) before capecitabine treatment, with a stable international normalized ratio (INR; range, 0.9-3.3). The dose of capecitabine ranged from 1.6 g/m2 to 2 g/m2 per day. Thirteen patients (11 on warfarin) had an INR > 3 (range, 3.23-11.5), resulting in a probability of an INR > 3 of 32% in the warfarin group versus 4% for those not on warfarin (P = 5.1 x 10(-14)) at 130 days. Six patients required a warfarin dose reduction (1-2.5 mg decrease). There were 7 episodes of bleeding (all gastrointestinal; 5 with warfarin). Seven patients who experienced bleeding had INRs ranging from 1.06 to 8 (average, 3.31) at the time bleeding occurred. Of the 7 bleeding episodes, 5 patients required transfusions, averaging 3.25 units of red blood cells and 2.4 units of fresh frozen plasma. The incidence of bleeding at 130 days of treatment with capecitabine was 18% with warfarin v...Continue Reading
References
Sep 4, 1999·Chemotherapy·M C Brown
Dec 22, 1999·Pharmacotherapy·J M KolesarJ H Schiller
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas H CartwrightJoseph J Schulz
Nov 27, 2002·Clinical Colorectal Cancer·M S CopurE Chu
Aug 6, 2003·Acta Oncologica·M Wasif SaifJean L Grem
Aug 20, 2003·Clinical Oncology : a Journal of the Royal College of Radiologists·H C E BuyckP N Plowman
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ScheithauerUNKNOWN X-ACT Study Group
Jul 27, 2004·Cancer·Yehuda Z PattThomas D Brown
Oct 21, 2004·Anti-cancer Drugs·M Wasif SaifRobert B Diasio
Feb 12, 2005·Seminars in Thrombosis and Hemostasis·Anna Falanga
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melina VersoStefano Mosca
Jul 15, 2005·The Annals of Pharmacotherapy·Laurel M Janney, Nancee V Waterbury
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ross CamidgeDuncan Jodrell
Jul 26, 2005·Journal of Chemotherapy·K Isaacs, N Haim
Aug 4, 2005·Nature Clinical Practice. Oncology·Gloria A PetraliaAjay K Kakkar
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Wasif SaifMartin R Johnson
Citations
May 4, 2007·Journal of General Internal Medicine·Adam J RoseElaine M Hylek
Jul 31, 2010·Case Reports in Medicine·Giovanni Giunta
Nov 1, 2006·Women's Health·Hernán Cortés-Funes
Nov 1, 2011·Clinical Therapeutics·Denys T LauJune M McKoy
Apr 10, 2009·Critical Reviews in Oncology/hematology·Muhammad W Saif, Stuart M Lichtman
Jun 25, 2009·The British Journal of Dermatology·G GuptaA Sergeant
Dec 7, 2010·Pharmacotherapy·Sachin R ShahSarah M Gressett Ussery
Jun 25, 2016·Cancer Chemotherapy and Pharmacology·Tsuyoshi HataTaroh Satoh
Jun 9, 2010·The Cancer Journal·Derek G Power, Stuart M Lichtman
Jan 17, 2019·Expert Opinion on Pharmacotherapy·Nauman S SiddiquiMuhammad Wasif Saif
Feb 5, 2019·Current Oncology Reports·Harsh K Patel, Alok A Khorana
Feb 5, 2019·Drugs & Aging·Manvi SharmaHolly M Holmes
Jan 29, 2010·Cancer Chemotherapy and Pharmacology·Masaru NakajimaYasufumi Sawada
May 4, 2010·Current Oncology Reports·Thorvardur R Halfdanarson, Aminah Jatoi
Feb 28, 2009·Anti-cancer Drugs·Giuseppe AprileFabio Puglisi
Jul 6, 2019·Journal of Clinical Pharmacology·Jacqueline RamírezManish R Sharma
Apr 18, 2008·Anti-cancer Drugs·Muhammad Wasif SaifKostas N Syrigos